{
    "nct_id": "NCT03596372",
    "official_title": "An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the Anti-CEACAM6 Antibody BAY1834942 in Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Male or female patients aged â‰¥ 18 years\n* Patients with histologically confirmed advanced/ metastatic solid tumors: Dose escalation: solid tumor types with a expression of CEACAM6 (gastric/ GEJ cancer, esophageal cancer, NSCLC, CRC, pancreatic cancer, cervical cancer, breast cancer, bladder cancer, head and neck squamous cell cancer, bile duct cancer); Dose expansion: advanced adeno NSCLC, CRC and gastric/ GEJ adenocarcinoma.\n* ECOG-PS of 0 to 1.\n* Adequate organ function (bone marrow, liver, kidneys).\n* Adequate coagulation function.\n* Adequate cardiac function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with active symptomatic or untreated brain metastases; possible exceptions for patients with treated asymptomatic central nervous system metastases\n* Active autoimmune disease\n* History or evidence of active pulmonary fibrosis, organizing pneumonia, or pneumonitis.\n* Risk factors for bowel obstruction or bowel perforation\n* History of cardiac disease\n* Uncontrolled arterial hypertension despite optimal medical management\n* Clinically relevant findings in electrocardiogram\n* HIV infection\n* Active HBV or HCV infection",
    "miscellaneous_criteria": ""
}